ESMO 2018 | Matching treatment to molecular profiles in endometrial cancer

Carien Creutzberg, MD, PhD, of the Leiden University Medical Center, Leiden, Netherlands, touches on challenges in the treatment of endometrial cancer and suggests how molecular profiling can improve patient prospects, at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. Prof. Creutzberg suggests Pol ε mutated cancers may respond best to checkpoint inhibitors, while p53 mutated tumors may respond to PARP inhibitors.